Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000196254 | SCV000255213 | uncertain significance | Bardet-Biedl syndrome | 2021-09-01 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine with glycine at codon 487 of the BBS12 protein (p.Arg487Gly). The arginine residue is moderately conserved and there is a moderate physicochemical difference between arginine and glycine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with BBS12-related conditions. ClinVar contains an entry for this variant (Variation ID: 216822). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Counsyl | RCV000665030 | SCV000789085 | uncertain significance | Bardet-Biedl syndrome 12 | 2017-01-05 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003165477 | SCV003876911 | uncertain significance | Inborn genetic diseases | 2023-02-27 | criteria provided, single submitter | clinical testing | The c.1459A>G (p.R487G) alteration is located in exon 2 (coding exon 1) of the BBS12 gene. This alteration results from a A to G substitution at nucleotide position 1459, causing the arginine (R) at amino acid position 487 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV003897430 | SCV004717067 | uncertain significance | BBS12-related disorder | 2024-02-29 | criteria provided, single submitter | clinical testing | The BBS12 c.1459A>G variant is predicted to result in the amino acid substitution p.Arg487Gly. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.050% of alleles in individuals of East Asian descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Natera, |
RCV000665030 | SCV001454980 | uncertain significance | Bardet-Biedl syndrome 12 | 2020-03-11 | no assertion criteria provided | clinical testing |